Cargando…
The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro
BACKGROUND: The NSAID mavacoxib (Trocoxcil™) is a recently described selective COX-2 inhibitor used for the management of inflammatory disease in dogs. It has a long plasma half-life, requiring less frequent dosing and supporting increased owner compliance in treating their dogs. Although the use of...
Autores principales: | Pang, Lisa Y, Argyle, Sally A, Kamida, Ayako, Morrison, Katherine O’Neill, Argyle, David J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172958/ https://www.ncbi.nlm.nih.gov/pubmed/25190452 http://dx.doi.org/10.1186/s12917-014-0184-9 |
Ejemplares similares
-
Global Gene Expression Analysis of Canine Osteosarcoma Stem Cells Reveals a Novel Role for COX-2 in Tumour Initiation
por: Pang, Lisa Y., et al.
Publicado: (2014) -
Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis
por: Payne-Johnson, M, et al.
Publicado: (2015) -
Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib
por: Salichs, Marta, et al.
Publicado: (2022) -
Use of multi-color flow cytometry for canine immune cell characterization in cancer
por: Parys, Maciej, et al.
Publicado: (2023) -
COX-2 Silencing in Canine Malignant Melanoma Inhibits Malignant Behaviour
por: Silveira, Tatiany L., et al.
Publicado: (2021)